Xeltis has appointed Luc Verhees as its new Vice President of Clinical Business Development, further strengthening the Company's leadership team as it expands its clinical presence following the approval of an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a US pivotal study for aXess, its restorative vascular access conduit.
Who to call at Xeltis, and when
A new leader at Xeltis brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Xeltis raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Xeltis, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Xeltis
Location
Eindhoven, North Brabant, Netherlands
About
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. The Company seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. Xeltis' proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient's own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Xeltis changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
EindhovenManufacturingBiotechnologyHealth Care